Address
1167 Massachusetts Avenue
Arlington, MA 02476
United States of America (the)
Phone
781 996 5252
Website
Sector
Healthcare
Industry
Biotechnology
Employees
38
First IPO Date
July 20, 2017
| Name | Title | Pay | Year Born |
| Avi Minkowitz | CEO, CFO & Director | 0 | 1988 |
| Mary Reumuth | Treasurer & Secretary | 1.01M | 1975 |
| Jill S. Steier | Executive Director of Investor Relations & Corporation Communications | 0 | N/A |
| Vincent Kosewski | Senior Vice President of Manufacturing & Supply Chain Management | 0 | 1963 |
| Francis S. Mah | Chief Medical Advisor | 0 | N/A |
| Justin Hanes | Founder & Chair of the Scientific Advisory Board | 0 | N/A |
| Carl Rennie | Executive Director of Account Management | 0 | N/A |
| Patrick Bedell | Executive Director of Trade & Alternate Channels | 0 | N/A |
| Josiah Craver | Senior Vice President & Corporate Controller | 0 | N/A |
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.